Neurodegenerative Disorders

Many neurodegenerative diseases share common pathological features: the misfolding and aggregation of key proteins. Under normal circumstances, cellular mechanisms efficiently degrade these proteins into their components for recycling. However, in some cases the misfolding leads to protein aggregation, which in turn can lead into an aggregation cascade that is self-propagating. Ultimately, misfolding of proteins and protein aggregation undermine a cell’s operational efficiency and the process becomes toxic.

TauRx is researching treatments that have the potential to modify the disease course in conditions that involve protein aggregation pathology and has pioneered a range of unique assays needed to develop and test these treatments. The Company’s protein aggregation inhibitors have the potential to target proteins in the following neurodegenerative conditions:

  • Alzheimer’s disease (tau)
  • Behavioural variant frontotemporal dementia or bvFTD (tau and TDP-43)
  • Chronic traumatic encephalopathy (tau)
  • Progressive supranuclear palsy (tau)
  • Cortico-basal degeneration (tau)
  • Parkinson’s disease (synuclein)
  • Huntington’s disease (huntingtin and tau)
  • Amyotrophic lateral sclerosis (TDP43)
Back to The Science